Enveric Biosciences (NASDAQ:ENVB) Announces Quarterly Earnings Results

Enveric Biosciences (NASDAQ:ENVB) issued its quarterly earnings data on Friday. The company reported ($0.57) earnings per share (EPS) for the quarter, Zacks reports.

Enveric Biosciences Price Performance

Enveric Biosciences stock traded down $0.01 during midday trading on Friday, hitting $1.51. The company’s stock had a trading volume of 17,393 shares, compared to its average volume of 32,344. Enveric Biosciences has a 1-year low of $1.17 and a 1-year high of $13.25. The company has a 50-day moving average price of $1.47 and a two-hundred day moving average price of $1.89. The company has a market cap of $6.79 million, a price-to-earnings ratio of -0.12 and a beta of 1.23.

Wall Street Analysts Forecast Growth

Several research firms recently weighed in on ENVB. Wall Street Zen raised Enveric Biosciences from a “sell” rating to a “hold” rating in a report on Sunday, August 23rd. Weiss Ratings restated a “sell (e+)” rating on shares of Enveric Biosciences in a research note on Thursday, October 15th. One analyst has rated the stock with a Sell rating. According to data from MarketBeat, the stock has an average rating of “Sell”.

Enveric Biosciences Company Profile

Enveric Biosciences, Inc. is a biotechnology company focused on discovering and developing novel small-molecule therapeutics for cancer and central nervous system disorders. The company’s research uses insights from cannabinoid science and psychedelic-inspired compounds to identify potential treatments for conditions with significant unmet medical needs. Enveric has developed a portfolio of proprietary drug candidates and intellectual property, including programs aimed at mental health conditions such as depression and other neurological disorders, as well as therapies intended to address cancer-related symptoms and supportive-care needs.